Growth and Growth Hormone Use in Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 251

[66] Sims NA, Clement-Lacroix P, Da Ponte F, Bouali Y, Binart N,
Moriggl R, et al. Bone homeostasis in growth hormone recep-
tor-null mice is restored by IGF-I but independent of Stat5. J
Clin Invest 2000;106(9):1095-103.
[67] Yakar S, Canalis E, Sun H, Mejia W, Kawashima Y, Nasser P,
et al. Serum IGF-1 determines skeletal strength by regulating
subperiosteal expansion and trait interactions. J Bone Miner Res
2009;24(8):1481-92.
[68] Wit JM, Kamp GA, Rikken B. Spontaneous growth and response
to growth hormone treatment in children with growth hor-
mone deiciency and idiopathic short stature. Pediatr Res
1996;39(2):295-302.
[69] Maheshwari HG, Silverman BL, Dupuis J, Baumann G.
Phenotype and genetic analysis of a syndrome caused by an
inactivating mutation in the growth hormone-releasing hor-
mone receptor: dwarism of Sindh. J Clin Endocrinol Metab
1998;83(11):4065-74.
[70] Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Francke
U. Growth hormone receptor deiciency in Ecuador. J Clin
Endocrinol Metab 1999;84(12):4436-43.
[71] Laron Z. Laron syndrome (primary growth hormone resistance
or insensitivity): the personal experience 1958-2003. J Clin
Endocrinol Metab 2004;89(3):1031-44.
[72] Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki
J, et al. Growth hormone insensitivity associated with a
STAT5b mutation. N Engl J Med 2003;349(12):1139-47.
[73] Hwa V, Camacho-Hubner C, Little BM, David A, Metherell LA,
El-Khatib N, et al. Growth hormone insensitivity and severe
short stature in siblings: a novel mutation at the exon 13-intron
13 junction of the STAT5b gene. Horm Res 2007;68(5):218-24.
[74] Hogler W, Shaw N. Childhood growth hormone deiciency,
bone density, structures and fractures: scrutinizing the evi-
dence. Clin Endocrinol 2010;72(3):281-9.
[75] Reiter EO. The somatomedins: involvement in growth pro-
cesses and disorders. Compr Ther 1983;9(2):45-55.
[76] Plotnick L. Growth, growth hormone, and pituitary disorders
Oski FDAC, Feigin RD, editors. Principles and practice of pedi-
atrics (2nd ed.). Philadelphia, PA: JB Lippincott; 1994. p. 1973-81.
[77] Regal M, Paramo C, Sierra SM, Garcia-Mayor RV. Prevalence
and incidence of hypopituitarism in an adult Caucasian popula-
tion in northwestern Spain. Clin Endocrinol 2001;55(6):735-40.
[78] Franklin SL, Geffner ME. Growth hormone: the expansion of
available products and indications. Pediatr Clin North Am
2011;58(5):1141-65.
[79] Clark P, Rogol A. Growth hormones and sex steroid interac-
tions at puberty Rosenfeld R, editor. Endocrinology and metab-
olism clinics of North America: growth and growth disorders.
Philadelphia, PA: WB Saunders; 1996. p. 665-81.
[80] Sizonenko PC, Clayton PE, Cohen P, Hintz RL, Tanaka T, Laron
Z. Diagnosis and management of growth hormone deiciency
in childhood and adolescence. Part 1: diagnosis of growth hor-
mone deiciency. Growth Horm IGF Res 2001;11(3):137-65.
[81] Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown
R, et al. Update of guidelines for the use of growth hormone
in children: the lawson wilkins pediatric endocrinology society
drug and therapeutics committee. J Pediatr 2003;143(4):415-21.
[82] Frasier SD. A preview of growth hormone stimulation tests in
children. Pediatrics 1974;53(6):929-37.
[83] Grimberg A, De Leon D. Disorders of growth Thomas Moshang
J, editor. Pediatric endocrinology: the requisites in pediatrics (1st
ed.). St. Louis, MO: Elsevier Mosby; 2005. p. 127-67.
[84] Cohen P. Clinical management of growth hormone therapy for
children. Manag Care 2009;18(8 Suppl 6):4-9.
[85] Consensus guidelines for the diagnosis and treatment of growth
hormone (GH) deficiency in childhood and adolescence:

summary statement of the GH Research Society. GH Research
Society. J Clin Endocrinol Metab 2000;85(11):3990-3.
[86] AACE medical guidelines for clinical practice for growth hor-
mone use in adults and children. Endocrine Practice 2003;9:
64-76.
[87] Marini JC, Bordenick S, Heavner G, Rose S, Hintz R, Rosenfeld
R, et al. The growth hormone and somatomedin axis in short
children with osteogenesis imperfecta. J Clin Endocrinol Metab
1993;76(1):251-6.
[88] Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S,
Zamboni G, et al. Growth hormone treatment in osteogenesis
imperfecta with quantitative defect of type I collagen synthesis.
J Pediatr 1996;129(3):432-9.
[89] Ernst M, Rodan GA. Increased activity of insulin-like growth
factor (IGF) in osteoblastic cells in the presence of growth
hormone (GH): positive correlation with the presence of
the GH-induced IGF-binding protein BP-3. Endocrinology
1990;127(2):807-14.
[90] Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT,
Slootweg MC. Growth hormone and bone. Endocr Rev
1998;19(1):55-79.
[91] Marini JC, Hopkins E, Glorieux FH, Chrousos GP, Reynolds JC,
Gundberg CM, et al. Positive linear growth and bone responses
to growth hormone treatment in children with types III and IV
osteogenesis imperfecta: high predictive value of the carboxy-
terminal propeptide of type I procollagen. J Bone Miner Res
2003;18(2):237-43.
[92] Kemp SF, Frindik JP. Emerging options in growth hormone
therapy: an update. Drug Des Devel Ther 2011;5:411-9.
[93] Cook DM, Rose SR. A review of guidelines for use of growth
hormone in pediatric and transition patients. Pituitary
2012;15(3):301-10.
[94] Lindgren AC, Ritzen EM. Five years of growth hormone
treatment in children with Prader-Willi syndrome. Swedish
National Growth Hormone Advisory Group. Acta Paediatr
Suppl 1999;88(433):109-11.
[95] Ritzen EM, Lindgren AC, Hagenas L, Marcus C, Muller J,
Blichfeldt S. Growth hormone treatment of patients with
Prader-Willi syndrome. Swedish Growth Hormone Advisory
Group. J Pediatr Endocrinol Metab 1999;12(Suppl. 1):345-9.
[96] Thacker MJ, Hainline B, Dennis-Feezle L, Johnson NB,
Pescovitz OH. Growth failure in Prader-Willi syndrome
is secondary to growth hormone deiciency. Horm Res
1998;49(5):216-20.
[97] Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M.
Utah Growth Study: growth standards and the prevalence of
growth hormone deiciency. J Pediatr 1994;125(1):29-35.
[98] Ross JL, Kowal K, Quigley CA, Blum WF, Cutler Jr. GB, Crowe B,
et al. The phenotype of short stature homeobox gene (SHOX) dei-
ciency in childhood: contrasting children with Leri-Weill dyschon-
drosteosis and Turner syndrome. J Pediatr 2005;147(4):499-507.
[99] Bang P, Bjerknes R, Dahlgren J, Dunkel L, Gustafsson J, Juul A,
et al. A comparison of different deinitions of growth response
in short prepubertal children treated with growth hormone.
Horm Res Paediatr 2011;75(5):335-45.

[100] Hertel NT, Eklof O, Ivarsson S, Aronson S, Westphal O, Sipila I,

et al. Growth hormone treatment in 35 prepubertal children with
achondroplasia: a ive-year dose-response trial. Acta Paediatr
2005;94(10):1402-10.

[101] Rothenbuhler A, Linglart A, Piquard C, Bougneres P. A pilot

study of discontinuous, insulin-like growth factor 1-dosing
growth hormone treatment in young children with FGFR3
N540K-mutated hypochondroplasia. J Pediatr 2012;160(5):849-53.

[102] Zivicnjak M, Schnabel D, Staude H, Even G, Marx M, Beetz R,

et al. Three-year growth hormone treatment in short children